z-logo
Premium
Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping
Author(s) -
Zaffaroni Nadia,
De Polo Daniela,
Villa Raffaella,
Della Porta Chiara,
Collini Paola,
Fabbri Alessandra,
Pilotti Silvana,
Daidone Maria Grazia
Publication year - 2003
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1401
Subject(s) - telomerase , immunophenotyping , biology , cancer research , carcinoid tumour , phenotype , pathology , gene product , gene expression , gene , microbiology and biotechnology , flow cytometry , medicine , genetics
Telomerase activity was examined by the telomeric repeat amplification protocol (TRAP) assay in 38 neuroendocrine (NE) lung tumours. A significantly ( p = 0.001) different frequency of telomerase positivity was observed among different histological tumour types. Specifically, a positive TRAP signal was observed in 14 of 15 (93%) small cell lung cancers (SCLCs), 7 of 8 (87%) large‐cell NE carcinomas (LCNECs), and only 1 of 15 (7%) typical carcinoid tumours. When telomerase activity was correlated with the gene product‐based immunophenotypic profile of individual tumours, it was found that the absence of telomerase activity was associated with a lack of bcl‐2, p53, and c‐kit expression, and characterized by a low proliferation index consistent with the absence of cdk‐4 expression and the presence of the cdk inhibitor Rb. Such a phenotype was appreciable in most of the carcinoid tumours. Conversely, telomerase‐positive tumours generally showed an immunophenotype consistent with gene product alterations (including high expression of bcl‐2, p53, and c‐kit, and loss of Rb) and were characterized by a high proliferation index. These telomerase data support the previously reported evidence for two genetically unrelated groups of NE lung tumours (SCLC, and to some extent LCNEC, versus carcinoid tumours) that have distinct phenotypic profiles. Copyright © 2003 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here